Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

Clinical trial NCT02859415 · TERMINATED

Trial details

NCT number: NCT02859415
Sponsor: National Cancer Institute (NCI)
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Esophageal Neoplasms Lung Neoplasms Mesothelioma Thymus Neoplasms Neoplasms, Germ Cell and Embryonal

Start date: 2019-08-08
Primary completion: 2019-12-06
Enrollment: 3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.